- Home
- ORIQ vs IFRX Comparison
ORIQ vs IFRX Comparison
Compare ORIQ & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIQ
- IFRX
- Stock Information
- Founded
- ORIQ 2024
- IFRX 2007
- Country
- ORIQ Singapore
- IFRX Germany
- Employees
- ORIQ N/A
- IFRX N/A
- Industry
- ORIQ
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- ORIQ
- IFRX Health Care
- Exchange
- ORIQ Nasdaq
- IFRX Nasdaq
- Market Cap
- ORIQ 87.6M
- IFRX 86.0M
- IPO Year
- ORIQ 2025
- IFRX 2017
- Fundamental
- Price
- ORIQ $10.18
- IFRX $1.27
- Analyst Decision
- ORIQ
- IFRX Strong Buy
- Analyst Count
- ORIQ 0
- IFRX 5
- Target Price
- ORIQ N/A
- IFRX $9.80
- AVG Volume (30 Days)
- ORIQ 8.0K
- IFRX 7.6M
- Earning Date
- ORIQ 01-01-0001
- IFRX 11-07-2025
- Dividend Yield
- ORIQ N/A
- IFRX N/A
- EPS Growth
- ORIQ N/A
- IFRX N/A
- EPS
- ORIQ N/A
- IFRX N/A
- Revenue
- ORIQ N/A
- IFRX $73,729.00
- Revenue This Year
- ORIQ N/A
- IFRX N/A
- Revenue Next Year
- ORIQ N/A
- IFRX $1,216.24
- P/E Ratio
- ORIQ N/A
- IFRX N/A
- Revenue Growth
- ORIQ N/A
- IFRX N/A
- 52 Week Low
- ORIQ $9.98
- IFRX $0.71
- 52 Week High
- ORIQ $10.20
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- ORIQ N/A
- IFRX 46.11
- Support Level
- ORIQ N/A
- IFRX $1.25
- Resistance Level
- ORIQ N/A
- IFRX $1.94
- Average True Range (ATR)
- ORIQ 0.00
- IFRX 0.20
- MACD
- ORIQ 0.00
- IFRX -0.01
- Stochastic Oscillator
- ORIQ 0.00
- IFRX 10.26
About ORIQ Origin Investment Corp I Ordinary Shares
Origin Investment Corp I is a blank check company.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.